ArticleClinical and experimental medicine2026
Serum TIMP-1 shows a potential association with metastatic disease in patients with pancreatic cancer: a pilot analysis without a healthy control cohort.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is most often diagnosed at an advanced stage, when distant metastases are already present and curative treatment options are limited. In this clinical context, biomarkers capable of reflecting tumor aggressiveness and metastatic potential are of particular relevance. Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been implicated in tumor invasion and metastatic dissemination; however, its clinical significance in pancreatic cancer remains incompletely defined. We analyzed TIMP-1 concentrations in serum and pancreatic tissue of 154 patients (108 malignant tumors, 46 benign lesions) using ELISA. Associations with clinical stage and the presence of distant metastases were assessed using non-parametric tests and ROC curve analysis. TIMP-1 levels were significantly higher in malignant compared with benign tumors, both in tissue (24.28 vs. 21.62 ng/mL; p = 0.0318) and serum (28.03 vs. 25.52 ng/mL; p = 0.0106). Serum TIMP-1 showed superior diagnostic accuracy (AUC = 0.796) compared to tissue TIMP-1 (AUC = 0.745). Patients with distant metastases exhibited significantly higher serum TIMP-1 levels than non-metastatic cases (28.33 vs. 26.53 ng/mL; p = 0.0046; AUC = 0.785). Serum TIMP-1 is associated with malignant and metastatic pancreatic disease and reflects a more aggressive tumor phenotype in patients with established pancreatic cancer. While the observed differences are modest and limit its applicability as a stand-alone diagnostic or screening biomarker, TIMP-1 may provide clinically relevant information regarding metastatic status and could contribute to prognostic stratification or multimarker approaches in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.